AskMed

Polycystic Ovary Syndrome: Diagnosis, Risks and Treatment

Polycystic ovary syndrome (PCOS) is a common, lifelong hormonal condition in which the ovaries release eggs irregularly or not at all and androgens, the hormones often called male hormones, are raised or show their effects on skin and hair. The World Health Organization estimates that it affects 10–13% of women of reproductive age, and that up to 70% of women who have it don't know. It can cause irregular or absent periods, excess facial or body hair, acne, thinning scalp hair and difficulty getting pregnant, and it raises the risk of type 2 diabetes, cardiovascular disease, endometrial cancer, depression and anxiety. It is now also called polyendocrine metabolic ovarian syndrome (PMOS), as the NHS now names it, because the old name wrongly suggests abnormal ovarian cysts. This guide follows the 2023 International Evidence-based Guideline for PCOS, from the diagnosis, now with the AMH blood test, to long-term risks and treatment by goal.

Much of what is written about PCOS predates the 2023 guideline, so you may read that an ultrasound is always needed or that clomiphene comes first for fertility; neither still holds. AskMed is a medical question app made for doctors, nurses, pharmacists, medical students and researchers. It searches clinical guidelines and studies before it answers, then links every claim to its source. Ask it whether you need an ultrasound for a PCOS diagnosis if your periods are irregular and your testosterone is high, and it answers from the guideline's own recommendations.

Ask AskMed what the 2023 PCOS guideline says about your situation:

What is PCOS?

PCOS is a hormonal condition defined by a combination of three features: ovulatory dysfunction, which shows up as irregular or absent periods; hyperandrogenism, meaning raised androgen levels or their effects on skin and hair; and polycystic ovarian morphology, a high number of small follicles on the ovaries. The 2023 International Evidence-based Guideline, written by the International PCOS Network with 39 professional and consumer organisations covering 71 countries, confirmed a prevalence of 10–13% using the Rotterdam criteria and found it high across all ethnicities and world regions. The WHO says the cause is unknown, but that women with a family history of PCOS or type 2 diabetes are at higher risk; the NHS points to hormones such as insulin and testosterone not working properly. The guideline also treats PCOS as enduring: the diagnosis can be considered lifelong, and raised androgens can persist after menopause. PCOS affects metabolic and mental health, not only periods and fertility.

PCOS has a new name: PMOS

In May 2026, an international consensus published in The Lancet named the condition polyendocrine metabolic ovarian syndrome, or PMOS, and the NHS now says that PMOS used to be called PCOS. The authors, working with 56 academic, clinical and patient organisations and global surveys answered by 14,360 people with PCOS and health professionals, judged the old name inaccurate: it implies pathological ovarian cysts and hides the condition's endocrine and metabolic features, which they link to delayed diagnosis, fragmented care and stigma. The new name keeps the words polyendocrine, metabolic and ovarian to reflect a condition that affects several body systems, and a transition period with education is under way. The condition itself is the same, the 2023 guideline described here remains the international standard, and this guide uses PCOS, the name most people still search for.

What are the symptoms of PCOS?

The symptoms of PCOS vary from person to person and can change over time, the WHO notes, and most of them come either from irregular ovulation or from raised androgens. Irregular, infrequent or absent periods are the most typical sign, and periods can also be heavy or painful. Raised androgens cause hirsutism, meaning excess hair on the face, chest or back, along with acne or oily skin and thinning of the hair on the scalp in a female pattern. Difficulty getting pregnant is common, because ovulation is infrequent or absent. The NHS adds weight gain or difficulty losing weight, feeling very tired, depression or anxiety, and thick, dark patches of skin on the neck or armpits, known as acanthosis nigricans. Not everyone has every symptom, because a diagnosis needs only two of the three features: some people have high androgens with regular-looking cycles, and others have irregular cycles without excess hair.

PCOS is not only a condition of people with a higher weight. The guideline states that the raised risk of diabetes applies regardless of age and BMI, and that many women with PCOS experience weight stigma in healthcare. Insulin resistance is one of the risks the WHO links to PCOS; if you have been given a HOMA-IR result, the HOMA-IR calculator explains how that estimate is worked out.

How is PCOS diagnosed under the 2023 guideline?

PCOS is diagnosed in adults with the Rotterdam criteria as refined by the 2023 International Evidence-based Guideline: a person needs two of three features, once other conditions that look similar have been excluded. The three features are ovulatory dysfunction, usually seen as irregular cycles; clinical or biochemical hyperandrogenism, meaning hirsutism, acne or hair loss, or raised androgen levels in the blood; and polycystic ovarian morphology on ultrasound or, new in 2023, a raised anti-Müllerian hormone (AMH) level. If irregular cycles and hyperandrogenism are both present, the guideline says neither an ultrasound nor an AMH test is needed. Adolescents are different: both irregular cycles and hyperandrogenism are required, and ultrasound and AMH are not recommended, because there are no reliable ovary criteria for that age. Before the diagnosis is made, the guideline's algorithm excludes other causes with blood tests for thyroid-stimulating hormone (TSH), prolactin, 17-hydroxyprogesterone and follicle-stimulating hormone (FSH).

Adults: any 2 of these 3 1. Irregular cycles ovulatory dysfunction 2. High androgens hirsutism, acne, hair loss or blood test 3. Polycystic ovaries ultrasound, or a high AMH (adults only) Other causes excluded first: TSH, prolactin, 17-OHP, FSH
The 2023 guideline's version of the Rotterdam criteria. If 1 and 2 are both present, no ultrasound or AMH test is needed. Adolescents need both 1 and 2.

Irregular cycles: what counts

The guideline defines irregular cycles by the time since the first period (menarche), because cycles take a few years to settle:

High androgens: the hair score and the blood tests

Hirsutism on its own predicts raised androgens in adults, and the guideline measures it with the modified Ferriman-Gallwey score, counting a score of 4 to 6 or more as hirsutism depending on ethnicity. For blood tests, it recommends total testosterone together with the testosterone not bound to proteins, which can be calculated using sex hormone-binding globulin (SHBG); androstenedione and DHEAS may be checked if testosterone is not raised. High-quality assays, such as liquid chromatography-mass spectrometry, are preferred. Very high androgen levels call for a search for other causes, which the guideline lists as androgen-secreting tumours, congenital adrenal hyperplasia, Cushing's syndrome and ovarian hyperthecosis.

Ultrasound or AMH: the ovary criterion

In adults, polycystic ovarian morphology on ultrasound means 20 or more follicles in at least one ovary, or an ovarian volume of 10 mL or more; when image quality is limited, 10 or more follicles in a single cross-section can be used. A transvaginal scan is the most accurate if it is acceptable to the person. The 2023 update adds the serum AMH blood test as an alternative to ultrasound for this criterion in adults. AMH should not be used as a single diagnostic test, ultrasound and AMH should not both be used for the same criterion, and AMH should not yet be used in adolescents.

What are the long-term health risks of PCOS?

The long-term health risks of PCOS reach well beyond fertility, and the 2023 guideline lists them so that they can be checked for and prevented. The clearest is dysglycemia: in a 2018 meta-analysis of 40 studies in Human Reproduction Update, women with PCOS had higher odds of impaired glucose tolerance (odds ratio 3.26) and type 2 diabetes (odds ratio 2.87) than women without PCOS, and the guideline states that this risk is raised regardless of age and BMI. Women with PCOS should also be considered at increased risk of cardiovascular disease, and potentially of cardiovascular death, although overall cardiovascular risk before menopause is low. The guideline adds obstructive sleep apnea, independent of BMI, and a markedly higher risk of endometrial hyperplasia and endometrial cancer before menopause. In pregnancy, gestational diabetes, high blood pressure disorders, miscarriage, preterm birth and caesarean section are more common. The NHS also lists high blood pressure and fatty liver disease.

2.87×the odds of type 2 diabetes (2018 meta-analysis)
3.26×the odds of impaired glucose tolerance
2.79×the odds of endometrial cancer (2014 meta-analysis)
3.78×the odds of depressive symptoms (2017 meta-analysis)

Endometrial cancer: higher risk, low absolute numbers

Long-standing untreated amenorrhea, meaning a long absence of periods, is one of the risk factors for endometrial cancer that the guideline names. In a 2014 meta-analysis in Human Reproduction Update, Barry and colleagues found an odds ratio of 2.79 for endometrial cancer in women with PCOS, rising to 4.05 when women over 54 were left out; the risk of breast cancer was not increased. The authors stress that the increase must be judged against the relatively low incidence of endometrial cancer, and the guideline agrees that absolute risks remain low and does not recommend routine screening. Tell a doctor about bleeding after menopause, bleeding between periods or unusually heavy periods, which the NHS lists as symptoms of womb cancer. People with fatty liver disease can read more in our guide to fatty liver symptoms.

Mental health

Depression and anxiety are common in PCOS and are not explained by weight alone. A 2017 meta-analysis in Human Reproduction by Cooney and colleagues, covering 30 studies from 10 countries, found higher odds of depressive symptoms (odds ratio 3.78) and anxiety symptoms (odds ratio 5.62) in women with PCOS, and the odds stayed higher when women were matched for BMI. The guideline asks clinicians to screen all adults and adolescents with PCOS for depression and all adults for anxiety, and to consider eating disorders.

Which check-ups follow a PCOS diagnosis?

After a PCOS diagnosis, the 2023 guideline recommends a set of check-ups aimed at the long-term risks, starting at diagnosis whatever a person's age or weight. Glycemic status should be assessed at diagnosis in all adults and adolescents with PCOS and reassessed every 1 to 3 years, depending on other risk factors for diabetes, and the oral glucose tolerance test is named as the most accurate test. An oral glucose tolerance test should also be considered when planning a pregnancy or seeking fertility treatment, and offered during pregnancy at 24 to 28 weeks. All women with PCOS should be assessed for cardiovascular risk factors: a lipid profile at diagnosis regardless of age and BMI, and blood pressure measured every year and when planning a pregnancy or seeking fertility treatment. Clinicians should ask about symptoms of obstructive sleep apnea and screen with validated tools or refer if they are present. Depression and anxiety screening completes the list.

Turning those recommendations into a plan for one person depends on age, weight, family history and pregnancy plans, and the interval for glucose checks is set by individual risk factors. Ask AskMed how often glucose should be rechecked in PCOS when a parent has type 2 diabetes, or which tests the guideline suggests before fertility treatment, and the answer cites the recommendation it comes from, so you can take a checked list to your next appointment.

Ask AskMed which PCOS check-ups apply to you:

How is PCOS treated? Options by goal

PCOS treatment is chosen by goal, because no single medicine treats every feature, and the 2023 guideline builds care around what matters most to the person: regular cycles, less hair or acne, metabolic health, weight, or a pregnancy. Lifestyle comes first for everyone: healthy eating and physical activity are recommended for all women with PCOS to improve metabolic health, including fat around the waist, and the guideline suggests that adults aim for at least 150 to 300 minutes of moderate-intensity activity a week. If weight loss is a goal, a tailored energy deficit can help. For irregular cycles and hirsutism, the main medicine is the combined oral contraceptive pill, and the guideline does not prefer any specific type. Metformin is the main medicine for metabolic health, and anti-obesity medicines, including GLP-1 receptor agonists, can be added to lifestyle changes. The WHO notes that there is no cure for PCOS, but treatment can improve quality of life.

The guideline compares the two main medicines directly: the combined pill could be used over metformin for hirsutism, and metformin over the pill for metabolic goals. Taking both may add little for adults with a BMI of 30 or less but may help groups at high metabolic risk. Metformin's side effects are mostly mild stomach and bowel symptoms that tend to settle. The pill's contraindications and side effects need to be weighed for each person.

Goals often overlap and change: someone may want less facial hair now and a pregnancy next year, and the options for one goal can rule out another, since anti-androgens need reliable contraception. Ask AskMed which treatments the guideline lists for excess hair in someone planning a pregnancy, or how metformin and the combined pill compare for your main goal, and each statement links to the recommendation or study it comes from, ready to discuss with your doctor.

Compare PCOS treatment options for your goal in AskMed:

How is infertility treated in PCOS?

Infertility in PCOS usually comes from infrequent or absent ovulation, so treatment aims to make ovulation happen, and the 2023 guideline makes letrozole, an aromatase inhibitor, the first-line medicine for anovulatory infertility when there are no other fertility problems. Letrozole is preferred over clomiphene because it works better: in a 2014 New England Journal of Medicine trial of 750 women with PCOS, 27.5% had a live birth with letrozole compared with 19.1% with clomiphene, and ovulation was more frequent too. Clomiphene, alone or combined with metformin, remains an option. Gonadotrophins, hormone injections that stimulate the ovaries, are second-line; they give higher live birth and ovulation rates than clomiphene but need close monitoring to avoid multiple pregnancies. Laparoscopic ovarian surgery could be second-line for women who do not ovulate with clomiphene, and IVF could be offered when first- or second-line ovulation induction has failed. Before any treatment, the guideline advises improving weight, blood pressure, smoking, alcohol, diet and nutrition where needed.

  1. Before trying: weight, blood pressure, smoking, alcohol, diet and nutrition, plus a glucose test.
  2. First line: letrozole; clomiphene, alone or with metformin, is an alternative.
  3. Second line: gonadotrophins or laparoscopic ovarian surgery.
  4. Third line: IVF, with single-embryo transfer to limit multiple pregnancies.
The order of fertility treatment for anovulatory infertility in PCOS, from the 2023 international guideline.

In the 2014 trial, twin pregnancies occurred in 3.4% of pregnancies with letrozole and 7.4% with clomiphene, a difference that was not statistically significant, and pregnancy loss rates were similar. Clomiphene caused more hot flushes, while letrozole caused more fatigue and dizziness. With IVF, the guideline notes that elective single-embryo transfer keeps the number of multiple pregnancies down. Fertility treatment is planned by a specialist, who sets the medicine and the monitoring for each cycle.

When should you see a doctor about PCOS?

You should see a doctor about possible PCOS if your periods are irregular or have stopped, if excess facial or body hair, acne or scalp hair loss bothers you, if you are having difficulty getting pregnant, or if your symptoms are affecting your everyday life, work or relationships, which is when the NHS advises seeing a GP. It is worth asking about PCOS if you also have dark, thickened skin patches, weight gain that is hard to shift, or a family history of PCOS or type 2 diabetes, which the WHO names as risk factors. A diagnosis matters even without plans for pregnancy, because the guideline recommends checking glucose, lipids and blood pressure and screening for depression and anxiety from the start. If you already have PCOS, see a doctor without delay about bleeding after menopause, bleeding between periods or unusually heavy periods. Seek urgent care for severe pelvic or abdominal pain, very heavy bleeding with dizziness or fainting, or thoughts of harming yourself.

Frequently asked questions

Can you have PCOS without cysts on your ovaries?

Yes. Polycystic ovaries are only one of three features, and a diagnosis needs two. Adults with irregular cycles and high androgens don't need an ultrasound at all. The "cysts" seen on a scan are small follicles, and the 2026 consensus dropped cysts from the name because the old name wrongly implied abnormal ovarian cysts.

Is PCOS the same as PMOS?

Yes. The NHS now calls the condition polyendocrine metabolic ovarian syndrome (PMOS) and says that PMOS used to be called polycystic ovary syndrome (PCOS). The new name comes from an international consensus published in The Lancet in 2026; it is the same condition under a new name.

Can an AMH blood test diagnose PCOS?

Not on its own. Since 2023, a raised AMH can replace the ultrasound for the polycystic ovary criterion in adults, but one other feature is still needed, AMH is not a single diagnostic test, and it should not yet be used in adolescents.

Can you get pregnant with PCOS?

Yes, many people with PCOS do, sometimes with treatment to help them ovulate. Letrozole is the first-line medicine; in a 2014 trial, 27.5% of women with PCOS who took it had a live birth, compared with 19.1% on clomiphene.

Does PCOS go away after menopause?

Not necessarily. The 2023 guideline says a PCOS diagnosis can be considered lifelong, and raised androgens can persist after menopause. The metabolic and cardiovascular risks also continue, so check-ups stay useful.

Do you have to be overweight to have PCOS?

No. PCOS occurs at any weight, and the guideline states that the raised risk of type 2 diabetes applies regardless of BMI. Excess weight can make symptoms and risks worse, which is why lifestyle care is recommended for everyone.

Sources

  1. Teede HJ, Tay CT, Laven JJE, et al.; International PCOS Network. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469.
  2. World Health Organization. Polycystic ovary syndrome. Fact sheet, 22 January 2026.
  3. NHS. Polyendocrine metabolic ovarian syndrome (PMOS). Last reviewed 30 June 2026.
  4. Teede HJ, Khomami MB, Morman R, et al.; Global Name Change Consortium. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329-2339.
  5. Kakoly NS, Khomami MB, Joham AE, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update. 2018;24(4):455-467.
  6. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748-758.
  7. Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017;32(5):1075-1091.
  8. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119-129.
  9. NHS. Symptoms of womb (uterine) cancer.

Cited medical answers
you can trust.

AskMed on iPhone, iPad, Android and the web.